Magnolol and Honokiol Exert a Synergistic Anti-tumor Effect Through Autophagy and Apoptosis in Human Glioblastomas

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Apr 14

PMID 27074557

Citations 28

Authors

Yu-Chen Cheng

Dueng-Yuan Hueng

Hua-Yin Huang

Jang-Yi Chen

Ying Chen

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GBM) is a malignant brain tumor associated with a high mortality rate. The aim of this study is to investigate the synergistic effects of honokiol (Hono) and magnolol (Mag), extracted from Magnolia officinalis, on cytotoxicity and inhibition of human GBM tumor progression in cellular and animal models. In comparison with Hono or Mag alone, co-treatment with Hono and Mag (Hono-Mag) decreased cyclin A, D1 and cyclin-dependent kinase 2, 4, 6 significantly, leading to cell cycle arrest in U87MG and LN229 human glioma cells. In addition, phosphorylated phosphoinositide 3-kinase (p-PI3K), p-Akt, and Ki67 were decreased after Hono-Mag treatment, showing proliferation inhibition. Hono-Mag treatment also reduced p-p38 and p-JNK but elevated p-ERK expression. Besides, Hono-Mag treatment induced autophagy and intrinsic and extrinsic apoptosis. Both ERK and autophagy inhibitors enhanced Hono-Mag-induced apoptosis in LN229 cells, indicating a rescuer role of ERK. In human GBM orthotopic xenograft model, the Hono-Mag treatment inhibited the tumor progression and induced apoptosis more efficiently than Temozolomide, Hono, or Mag group. In conclusion, the Hono-Mag exerts a synergistic anti-tumor effect by inhibiting cell proliferation and inducing autophagy and apoptosis in human GBM cells. The Hono-Mag may be applied as an adjuvant therapy to improve the therapeutic efficacy of GBM treatment.

Citing Articles

Honokiol Is More Potent than Magnolol in Reducing Head and Neck Cancer Cell Growth.

Kleszcz R, Dorna D, Stawny M, Paluszczak J Curr Issues Mol Biol. 2024; 46(10):10731-10744.

PMID: 39451517 PMC: 11506259. DOI: 10.3390/cimb46100637.

Recent advance of herbal medicines in cancer- a molecular approach.

Ali M, Wani S, Salahuddin M, S N M, K M, Dey T Heliyon. 2023; 9(2):e13684.

PMID: 36865478 PMC: 9971193. DOI: 10.1016/j.heliyon.2023.e13684.

Magnolol as a Potential Anticancer Agent: A Proposed Mechanistic Insight.

Wang X, Liu Q, Fu Y, Ding R, Qi X, Zhou X Molecules. 2022; 27(19).

PMID: 36234977 PMC: 9570903. DOI: 10.3390/molecules27196441.

Elucidating the Anti-Tumorigenic Efficacy of Oltipraz, a Dithiolethione, in Glioblastoma.

Kapoor-Narula U, Lenka N Cells. 2022; 11(19).

PMID: 36231019 PMC: 9562012. DOI: 10.3390/cells11193057.

Evodiamine suppresses the progression of non-small cell lung carcinoma via endoplasmic reticulum stress-mediated apoptosis pathway and .

Li Y, Wang Y, Wang X, Jin L, Yang L, Zhu J Int J Immunopathol Pharmacol. 2022; 36:3946320221086079.

PMID: 35388733 PMC: 9003648. DOI: 10.1177/03946320221086079.

References

Luo J, Manning B, Cantley L . Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003; 4(4):257-62. DOI: 10.1016/s1535-6108(03)00248-4. View

Cheng Y, Sk U, Zhang Y, Ren X, Zhang L, Huber-Keener K . Rational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell death. PLoS One. 2012; 7(4):e35104. PMC: 3320619. DOI: 10.1371/journal.pone.0035104. View

Cuperlovic-Culf M, Touaibia M, St-Coeur P, Poitras J, Morin P, Culf A . Metabolic Effects of Known and Novel HDAC and SIRT Inhibitors in Glioblastomas Independently or Combined with Temozolomide. Metabolites. 2014; 4(3):807-30. PMC: 4192694. DOI: 10.3390/metabo4030807. View

Hirano T, Gotoh M, Oka K . Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cells. Life Sci. 1994; 55(13):1061-9. DOI: 10.1016/0024-3205(94)00641-5. View

Jeong J, Lee J, Chang K, Kim H . Honokiol exerts an anticancer effect in T98G human glioblastoma cells through the induction of apoptosis and the regulation of adhesion molecules. Int J Oncol. 2012; 41(4):1358-64. DOI: 10.3892/ijo.2012.1582. View

Liang J, Slingerland J . Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle. 2003; 2(4):339-45. View

Cai H, Xue Y, Li Z, Hu Y, Wang Z, Liu W . Roundabout4 suppresses glioma-induced endothelial cell proliferation, migration and tube formation in vitro by inhibiting VEGR2-mediated PI3K/AKT and FAK signaling pathways. Cell Physiol Biochem. 2015; 35(5):1689-705. DOI: 10.1159/000373982. View

Funa N, Reddy K, Bhandarkar S, Kurenova E, Yang L, Cance W . Shb gene knockdown increases the susceptibility of SVR endothelial tumor cells to apoptotic stimuli in vitro and in vivo. J Invest Dermatol. 2007; 128(3):710-6. DOI: 10.1038/sj.jid.5701057. View

Crane C, Panner A, Pieper R, Arbiser J, Parsa A . Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J Immunother. 2009; 32(6):585-92. PMC: 3795513. DOI: 10.1097/CJI.0b013e3181a8efe6. View

10.

Bredel M, Piribauer M, Marosi C, Birner P, Gatterbauer B, Fischer I . High expression of DNA topoisomerase IIalpha and Ki-67 antigen is associated with prolonged survival in glioblastoma patients. Eur J Cancer. 2002; 38(10):1343-7. DOI: 10.1016/s0959-8049(02)00065-5. View

11.

Vo V, Lee J, Lee H, Chun W, Lim S, Kim S . Inhibition of JNK potentiates temozolomide-induced cytotoxicity in U87MG glioblastoma cells via suppression of Akt phosphorylation. Anticancer Res. 2014; 34(10):5509-15. View

12.

Chen L, Lee W . P27/Kip1 is responsible for magnolol-induced U373 apoptosis in vitro and in vivo. J Agric Food Chem. 2013; 61(11):2811-9. DOI: 10.1021/jf400542m. View

13.

Liang W, Chou C, Chang H, Cheng J, Kuo D, Ko K . The mechanism of honokiol-induced intracellular Ca(2+) rises and apoptosis in human glioblastoma cells. Chem Biol Interact. 2014; 221:13-23. DOI: 10.1016/j.cbi.2014.07.012. View

14.

Amblard F, Govindarajan B, Lefkove B, Rapp K, Detorio M, Arbiser J . Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol. Bioorg Med Chem Lett. 2007; 17(16):4428-31. PMC: 2001289. DOI: 10.1016/j.bmcl.2007.06.024. View

15.

Lv X, Liu F, Shang Y, Chen S . Honokiol exhibits enhanced antitumor effects with chloroquine by inducing cell death and inhibiting autophagy in human non-small cell lung cancer cells. Oncol Rep. 2015; 34(3):1289-300. DOI: 10.3892/or.2015.4091. View

16.

Newlands E, Blackledge G, Slack J, Rustin G, Smith D, Stuart N . Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992; 65(2):287-91. PMC: 1977719. DOI: 10.1038/bjc.1992.57. View

17.

Hwang E, Park K . Magnolol suppresses metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in PC-3 human prostate carcinoma cells. Biosci Biotechnol Biochem. 2010; 74(5):961-7. DOI: 10.1271/bbb.90785. View

18.

Datta S, Brunet A, Greenberg M . Cellular survival: a play in three Akts. Genes Dev. 1999; 13(22):2905-27. DOI: 10.1101/gad.13.22.2905. View

19.

Kaushik G, Ramalingam S, Subramaniam D, Rangarajan P, Protti P, Rammamoorthy P . Honokiol induces cytotoxic and cytostatic effects in malignant melanoma cancer cells. Am J Surg. 2012; 204(6):868-73. PMC: 3522181. DOI: 10.1016/j.amjsurg.2012.09.001. View

20.

Pugazhenthi S, Nesterova A, Sable C, Heidenreich K, Boxer L, Heasley L . Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem. 2001; 275(15):10761-6. DOI: 10.1074/jbc.275.15.10761. View